Lorenzo Bermejo J, Hemminki K
Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Im Neuemheimer Feld 580, D-69120 Heidelberg, Germany.
Ann Oncol. 2005 Feb;16(2):322-9. doi: 10.1093/annonc/mdi041.
The prevalence of families eligible for BRCA1/2 mutation testing in the population burden of breast cancer was analysed and the aggregation of breast cancer in these families was explored.
The families of the Swedish Family-Cancer Database with at least three generations (N=944 723) were classified according to the criteria proposed by the German Consortium for Hereditary Breast and Ovarian Cancer for BRCA1/2 mutation testing. We calculated the proportion of women with breast cancer in the classified families and used standardised incidence ratios (SIRs) to estimate the risk of histology specific breast cancers in families with suspected BRCA1/2 mutations.
Families with two breast cancers before the age of 50 years included 1.8% of the breast cancer patients; 1% of the women with breast cancer belonged to families with breast and ovarian cancers. The SIR of female breast cancer was lowest in families with male breast cancer and highest in families with two women affected by breast cancer under the age of 50 years. The SIRs of medullary breast cancer agreed with the BRCA1 mutation prevalences detected by the German Consortium for Hereditary Breast and Ovarian Cancer.
Most of the breast malignancies in families with male breast cancer are likely to be related to BRCA2 mutations. Non-BRCA1/2 related effects are probably involved in the strong clustering of breast cancer in families with early onset breast and ovarian cancers.
分析了符合BRCA1/2突变检测条件的家族在乳腺癌人群负担中的患病率,并探讨了这些家族中乳腺癌的聚集情况。
根据德国遗传性乳腺癌和卵巢癌联盟提出的BRCA1/2突变检测标准,对瑞典家族癌症数据库中至少有三代人的家族(N = 944723)进行分类。我们计算了分类家族中患乳腺癌女性的比例,并使用标准化发病率(SIR)来估计疑似BRCA1/2突变家族中特定组织学类型乳腺癌的风险。
50岁前有两名乳腺癌患者的家族占乳腺癌患者的1.8%;1%的乳腺癌女性属于患有乳腺癌和卵巢癌的家族。男性乳腺癌家族中女性乳腺癌的SIR最低,50岁以下有两名女性患乳腺癌的家族中SIR最高。髓样乳腺癌的SIR与德国遗传性乳腺癌和卵巢癌联盟检测到的BRCA1突变患病率一致。
男性乳腺癌家族中的大多数乳腺恶性肿瘤可能与BRCA2突变有关。非BRCA1/2相关效应可能参与了早发性乳腺癌和卵巢癌家族中乳腺癌的强烈聚集。